BC Cancer Protocol Summary of Yttrium-90 for Transarterial Radioembolisation (TARE)

Protocol Code
UGIYTT

Tumour Group
Gastrointestinal

Contact Physician
Dr. Dave Liu
Dr. Hagen Kennecke

ELIGIBILITY:
Suitability for Yttrium-90 TARE therapy will be established via consultation with Vancouver General Hospital (VGH) or Kelowna General Hospital (KGH) Intervention Radiology, in accordance with the following eligibility criteria:

- Hepatocellular cancer with portal venous invasion
- Hepatocellular cancer with T3 tumours, potentially amenable to downstage for liver transplantation or resection
- Hepatic metastatic neuroendocrine tumours (NETs)
- Definable disease burden by imaging criteria
- Mesenteric vascular anatomy amenable to TARE
- A BC Cancer “Compassionate Access Program” request with appropriate clinical information for each patient must be approved prior to treatment

EXCLUSIONS:

- Presence of ascites or encephalopathy
- Infiltrative disease greater than 50% or Childs Pugh score greater than 8 (late B) for patients with hepatocellular carcinoma
- Extrahepatic disease for patients with hepatocellular carcinoma
- Extrahepatic disease that is life-limiting for patients with NETs
- Life expectancy less than 3 months
- Compromised hepatic function consisting of Total Bilirubin greater than 2.5 x ULN, hypoalbuminemia less than 3.0 g/dL, AST, ALT or ALP greater than 5 x ULN

TREATMENT:

Prescribing

- Written directive for prescribed dose (radioactivity) from VGH or KGH Nuclear Medicine physician in conjunction with VGH or KGH Interventional Radiology

Delivery of treatment

- Treatment must be performed in the VGH or KGH angiography suite
Call the GI Systemic Therapy physician at your regional cancer centre or the GI Systemic Therapy Chair Dr. Janine Davies at (604) 877-6000 or 1-800-670-3322 with any problems or questions regarding this treatment program.

References: